Bioasis Technologies Inc. Logo

Bioasis Technologies Inc.

BTI.V

(1.8)
Stock Price

0,01 CAD

0% ROA

0% ROE

0x PER

Market Cap.

397.070,00 CAD

0% DER

0% Yield

0% NPM

Bioasis Technologies Inc. Stock Analysis

Bioasis Technologies Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Bioasis Technologies Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (94.4%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

With a remarkably low PBV ratio (-0.14x), the stock offers substantial upside potential at a bargain price.

3 DER

The stock has a low debt to equity ratio (-82%), which means it has a small amount of debt compared to the ownership it holds

4 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

5 ROA

The stock's ROA (-541.15%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Bioasis Technologies Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Bioasis Technologies Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Sell
4 Stoch RSI Buy

Bioasis Technologies Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Bioasis Technologies Inc. Revenue
Year Revenue Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 369.124 100%
2016 512.966 28.04%
2017 589.844 13.03%
2018 1.422.030 58.52%
2019 606.384 -134.51%
2020 4.078.129 85.13%
2021 37.725 -10710.15%
2022 0 0%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Bioasis Technologies Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2006 0
2007 0 0%
2008 148.584 100%
2009 619.174 76%
2010 958.241 35.38%
2011 1.111.095 13.76%
2012 1.918.534 42.09%
2013 1.999.758 4.06%
2014 1.350.913 -48.03%
2015 841.048 -60.62%
2016 783.778 -7.31%
2017 946.808 17.22%
2018 1.954.286 51.55%
2019 2.033.624 3.9%
2020 1.238.122 -64.25%
2021 1.226.155 -0.98%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Bioasis Technologies Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2006 0
2007 0 0%
2008 924.719 100%
2009 1.497.127 38.23%
2010 1.224.763 -22.24%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 2.285.135 100%
2017 4.452.419 48.68%
2018 4.314.472 -3.2%
2019 3.174.445 -35.91%
2020 2.459.924 -29.05%
2021 2.408.351 -2.14%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Bioasis Technologies Inc. EBITDA
Year EBITDA Growth
2006 -5.000
2007 -143.214 96.51%
2008 -1.073.303 86.66%
2009 -2.116.301 49.28%
2010 -2.046.838 -3.39%
2011 -2.820.988 27.44%
2012 -4.877.204 42.16%
2013 -3.582.154 -36.15%
2014 -2.773.352 -29.16%
2015 -2.496.075 -11.11%
2016 -2.924.851 14.66%
2017 -5.176.336 43.5%
2018 -6.167.159 16.07%
2019 -5.123.080 -20.38%
2020 -22.819 -22350.94%
2021 -4.832.761 99.53%
2022 0 0%
2023 0 0%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Bioasis Technologies Inc. Gross Profit
Year Gross Profit Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 -54.679 100%
2016 83.115 165.79%
2017 121.976 31.86%
2018 1.411.587 91.36%
2019 606.384 -132.79%
2020 4.078.129 85.13%
2021 -17.192 23821.09%
2022 0 0%
2023 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Bioasis Technologies Inc. Net Profit
Year Net Profit Growth
2006 -5.000
2007 -131.131 96.19%
2008 -1.149.785 88.6%
2009 -2.217.690 48.15%
2010 -2.152.239 -3.04%
2011 -2.937.907 26.74%
2012 -4.960.765 40.78%
2013 -3.610.124 -37.41%
2014 -2.836.269 -27.28%
2015 -2.572.923 -10.24%
2016 -2.990.781 13.97%
2017 -5.307.938 43.65%
2018 -3.473.414 -52.82%
2019 -4.056.420 14.37%
2020 698.410 680.81%
2021 -2.960.092 123.59%
2022 0 0%
2023 0 0%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Bioasis Technologies Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Bioasis Technologies Inc. Free Cashflow
Year Free Cashflow Growth
2006 0
2007 -61.816 100%
2008 -550.718 88.78%
2009 -1.462.204 62.34%
2010 -1.404.327 -4.12%
2011 -1.812.455 22.52%
2012 -1.869.107 3.03%
2013 -2.824.320 33.82%
2014 -2.015.903 -40.1%
2015 -1.532.674 -31.53%
2016 -1.244.213 -23.18%
2017 -3.780.851 67.09%
2018 -3.231.737 -16.99%
2019 -3.298.652 2.03%
2020 1.771.476 286.21%
2021 -3.635.505 148.73%
2022 0 0%
2023 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Bioasis Technologies Inc. Operating Cashflow
Year Operating Cashflow Growth
2006 0
2007 -61.816 100%
2008 -547.566 88.71%
2009 -1.460.135 62.5%
2010 -1.390.757 -4.99%
2011 -1.782.285 21.97%
2012 -1.865.123 4.44%
2013 -2.824.320 33.96%
2014 -2.015.153 -40.15%
2015 -1.530.218 -31.69%
2016 -1.244.213 -22.99%
2017 -3.673.138 66.13%
2018 -3.229.675 -13.73%
2019 -3.298.652 2.09%
2020 1.771.476 286.21%
2021 -3.635.505 148.73%
2022 0 0%
2023 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Bioasis Technologies Inc. Capital Expenditure
Year Capital Expenditure Growth
2006 0
2007 0 0%
2008 3.152 100%
2009 2.069 -52.34%
2010 13.570 84.75%
2011 30.170 55.02%
2012 3.984 -657.28%
2013 0 0%
2014 750 100%
2015 2.456 69.46%
2016 0 0%
2017 107.713 100%
2018 2.062 -5123.71%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Bioasis Technologies Inc. Equity
Year Equity Growth
2006 85.001
2007 574.170 85.2%
2008 2.071.539 72.28%
2009 2.995.178 30.84%
2010 2.422.915 -23.62%
2011 1.987.047 -21.94%
2012 3.594.068 44.71%
2013 2.390.922 -50.32%
2014 2.005.175 -19.24%
2015 1.719.215 -16.63%
2016 363.405 -373.09%
2017 434.146 16.29%
2018 -546.656 179.42%
2019 -2.486.278 78.01%
2020 407.196 710.59%
2021 -1.917.362 121.24%
2022 0 0%
2023 0 0%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Bioasis Technologies Inc. Assets
Year Assets Growth
2006 90.001
2007 631.175 85.74%
2008 2.092.570 69.84%
2009 3.034.404 31.04%
2010 2.542.976 -19.32%
2011 2.147.837 -18.4%
2012 3.835.262 44%
2013 2.578.584 -48.74%
2014 2.211.700 -16.59%
2015 2.152.954 -2.73%
2016 1.110.928 -93.8%
2017 1.221.807 9.08%
2018 1.743.246 29.91%
2019 941.794 -85.1%
2020 3.276.361 71.25%
2021 2.265.898 -44.59%
2022 0 0%
2023 0 0%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Bioasis Technologies Inc. Liabilities
Year Liabilities Growth
2006 5.000
2007 57.005 91.23%
2008 21.031 -171.05%
2009 39.226 46.39%
2010 120.061 67.33%
2011 160.790 25.33%
2012 241.194 33.34%
2013 187.662 -28.53%
2014 206.525 9.13%
2015 433.739 52.38%
2016 747.523 41.98%
2017 787.661 5.1%
2018 2.289.902 65.6%
2019 3.428.072 33.2%
2020 2.869.165 -19.48%
2021 4.183.260 31.41%
2022 0 0%
2023 0 0%

Bioasis Technologies Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
0
Price to Earning Ratio
0x
Price To Sales Ratio
0x
POCF Ratio
0
PFCF Ratio
0
Price to Book Ratio
0
EV to Sales
0
EV Over EBITDA
0
EV to Operating CashFlow
0
EV to FreeCashFlow
0
Earnings Yield
0
FreeCashFlow Yield
0
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0
Graham NetNet
0

Income Statement Metrics

Net Income per Share
0
Income Quality
0
ROE
0
Return On Assets
0
Return On Capital Employed
0
Net Income per EBT
0
EBT Per Ebit
0
Ebit per Revenue
0
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0
Return on Tangible Assets
0
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
0
Shareholders Equity per Share
0
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0
Current Ratio
0
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Bioasis Technologies Inc. Dividends
Year Dividends Growth

Bioasis Technologies Inc. Profile

About Bioasis Technologies Inc.

Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.

CEO
Dr. Deborah Ann Rathjen B.Sc.
Employee
0
Address
157 Church Street
New Haven, 06510

Bioasis Technologies Inc. Executives & BODs

Bioasis Technologies Inc. Executives & BODs
# Name Age
1 Dr. Deborah Ann Rathjen B.Sc. (Hons.), FTSE, M.A.I.C.D., Ph.D., Q.C.
Executive Chairman, Chief Executive Officer & President
70
2 Mr. David P. Jenkins
Chief Financial Officer
70
3 Mr. Graeme Dick
Director of Investor Relations
70
4 Mr. Aaron Elton
Director of Marketing
70
5 Dr. Mei Mei Tian
Vice President & Head of External Research
70

Bioasis Technologies Inc. Competitors